GlassScriptPhysician profile
Nathan L Moore
NPI 1093829822
$1,396.34
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $597 · 2021: $507 · 2022: $15.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $179.54 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $178.09 | 2019-2021 | |
| Pfizer INC. | $171.43 | 2019-2021 | |
| Allergan, INC. | $119.84 | 2020 | |
| Novo Nordisk INC | $119.74 | 2019-2021 | |
| Lilly USA, LLC | $111.72 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $100.75 | 2019-2021 | |
| Amarin Pharma, INC. | $74.11 | 2019-2021 | |
| Abbvie INC. | $64.63 | 2021-2022 | |
| Astellas Pharma US INC | $60.80 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.69 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $35.13 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $34.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.15 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.89 | 2020-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $25.42 | 2020-2021 | |
| Genentech USA, INC. | $13.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.